
Elegance By Design: How The Taittinger Family Craft Champagne
In Champagne, virtually every house claims to maintain the delicate balance between tradition and evolution. It's a well peddled cliché, but, ultimately that's the game - showcase your past without looking old, stuffy and out of touch. Spread you fizz around the world and pop up in all the right places. Champagne Taittinger too have it all figured out. Internationally aspirational with a presence in all the major markets, the house is revered for both its great value cuvées, and its prestigious Blanc de Blancs 'Comtes de Champagne' - one of the world's best sparkling wines.
Family owned and protective of its traditions, the company thrives off nearly 300 years of winemaking history. There is far more to it than that of course. Underpinning the brand is a meticulous attention to detail, exemplified best through the art of blending. Taittinger's flagship Brut wine, 'La Française', is a carefully composed non-vintage blend (or should we say multi vintage?) drawn from three different grapes cultivated across more than 35 Cru vineyard sites. By contrast, 'Comtes de Champagne' is made exclusively from Chardonnay, but blended from the company's best sites. Together, they exemplify the precision and poise for which the house is known, a poise that can only be achieved through bending (vintages, grapes, vineyards), or what they call in Reims and Epernay, a ssemblage .
Here, blending is not all pragmatic technique, it is the orchestration of site, variety, and time into a single coherent voice. At Taittinger that voice is guided by Chardonnay, the grape Vitalie Taittinger describes as 'the soul of our style - elegant, precise, and full of finesse.' Yet the region's other grapes play essential roles: Pinot Noir brings backbone and red-fruit complexity, while Pinot Meunier rounds out the blend with supple texture and aromatic lift. As Clovis Taittinger notes, 'We have always favored a Chardonnay-dominant style. It's a deliberate choice that reflects our view of what makes a Champagne elegant and age-worthy.' Each grape is selected for what it can contribute to the final balance, but the profile is always guided by the inherent belief in the superiority of Chardonnay.
Vitalie Taittinger amongst the vines. David Picchiottino
Vitalie and her brother Clovis Taittinger are the latest generation to lead the company. Established in 1734 as Champagne Forest-Fourneaux, the house was bought in 1932 by Pierre Taittinger, marking the beginning of the family's global reputation for elegant Champagnes. In 2005, the Taittinger Group, which at the time also included luxury hotels and other businesses, was sold to the U.S. investment firm Starwood Capital. Led by Pierre-Emmanuel Taittinger, the family initiated a project to reclaim control of the wine business. Within a year they succeeded and backed by the French bank Crédit Agricole, the family repurchased the Champagne house and its historic cellars, restoring Taittinger to family hands.
Today the estate's holdings and grower relationships span the Côte des Blancs, Vallée de la Marne, and Montagne de Reims - each producing fruit with different characteristics. Villages like Chouilly bring ripe orchard fruit; Avize delivers mineral tension; Mesnil-sur-Oger contributes steely acidity and length. These are not generally interchangeable pieces, but essential components of a wider picture. With 288 hectares under vine, Taittinger is one of the largest domaine holders in Champagne. Yet, size alone means little without the technical understanding of how each site fits precisely into the puzzle.
For the Brut La Française, fruit from more than 35 villages is selected to construct a wine of impressive consistency. More than six million bottles a year of this are released and consumers expect one bottle to taste the same as the next. How is that possible? Typically composed of 40% Chardonnay, 35% Pinot Noir, and 25% Meunier, the aim of this blend is balance: delicacy without brittleness, complexity without excess. As Alexandre Ponnavoy, Taittinger's Chef de Cave, notes, 'We taste hundreds of vins clairs each year to make sure each element, no matter how small, fits the whole.'
Alexander Ponnovoy showcasing the 2014 vintage of Comtes de Champagne. Non Runner Media
At the other end of the spectrum lies Comtes de Champagne Blanc de Blancs, made exclusively from Chardonnay grown in five Grand Cru villages of the Côte des Blancs: Avize, Cramant, Chouilly, Oger, and Mesnil-sur-Oger. Here, the message of place is unfiltered. 'Each site gives a different energy' Ponnavoy says. 'Cramant is creamy and floral; Mesnil is sharp and saline; Chouilly adds generosity. We select only the fine first-press juice. Nothing else makes it into Comtes.'
Taittinger's approach to the three classic Champagne grapes is architectural in nature. Chardonnay accounts for 37% of the estate's plantings and drives the house style across the range. Pinot Noir, mostly grown in the Montagne de Reims, contributes structure and spice. Meunier, sourced largely from the Vallée de la Marne, softens and expands the palate. Yet even in blends like Les Folies de la Marquetterie - produced from a single vineyard with a majority of Pinot Noir - the wine is constructed to ensure that Chardonnay's character subtly dominates. As Clovis Taittinger puts it, 'Each grape is selected for what it contributes to the final shape. Chardonnay gives lift and clarity. It's the line that defines our wines.'
Red grapes harvested for Champagne Taittinger ANNEEMMANUELLE THION
Champagne lovers will know, time is not just a measure of age, it's a key aspect of a wine's personality, and in the increasingly unpredictable climate of northern France, reserve wines are critical to achieving consistency in non-vintage blends like 'La Française'. With vintage variation inevitable, these older wines are used not to mask inconsistency, but to temper extremes. '2012 was warm and opulent,' recalls Vitalie Taittinger, 'so we balanced it with fresher reserves. 2013 was taut and we softened it with older material. The 2014, as you can see in the 'Comtes', was naturally poised and required no correction - just time to shine.'
This delicate composition of vintages in the cellar is part of what makes a Champagne blend so complex and compelling. Inevitably, the conditions of the year will dictate what work needs to done. Vitalie emphasises her role is 'to guide the team in tasting and blending with rigor, ensuring nature's variations never overshadow the Taittinger signature. Consistency is our promise, delivered with patience and care.'
With 'Comtes de Champagne' the blending approach is altogether different. Here, there are no reserves, and no commercial need to keep things prescribed. When the vintage is good enough, it will stand alone. 'We produce 'Comtes' only in exceptional years,' says Ponnavoy. 'It's not about crafting a house style, it's about capturing the essence of a single harvest.'
Chardonnay is the Champagne Taittinger's key variety. Anne Emmanuelle Thion
Comtes de Champagne Blanc de Blancs is undoubtedly a purist's wine: 100% vintage specific, 100% Chardonnay, 100% first-press juice, 100% Grand Cru. Just 5% of the wine is matured for four months in new oak, a detail that adds gentle breadth without overpowering. Then comes the long quiet - over a decade in the family's Gallo-Roman chalk quarries located beneath the former Abbey of Saint-Nicaise in Reims. The eventual wine currently costs around $400 a bottle.
The 2014 vintage, recently released, is a vivid expression of Taittinger's work. 'Comtes is a love letter to Chardonnay and time,' says Chef de Cave Alexandre Ponnavoy. 'It's a cuvée that doesn't impose, but reveals.' A warm summer and naturally balanced acidity made 2014 an exceptional year for Chardonnay, and Ponnavoy's meticulous selection process across the region ensures that only the best fruit from the five Grand Cru parcels contribute to the final wine. 'Each village gives its own character, but together they form something unmistakably Taittinger: pure, precise, and timeless' he says.
They are clearly proud of their work, but to call Taittinger's approach to blending simply 'assembly' misses the point. Figuring out how to order the building blocks of Champagne is about listening - to the cues of the vintage, the voice of each vineyard, the evolution of the base wines in the cellar, and to a legacy that has evolved since 1734. 'Taittinger must reinvent itself and improve always,' says Vitalie. 'But above all, we must transmit heritage and respect for the past. We are guardians of this beautiful wine.'
That balance between innovation and origin lingers somewhere in every cuvée. As Claude Taittinger, who took over from his brother Pierre in 1960 and spearheaded the company for decades, once reflected, 'We proceed bit by bit to elaborate a Champagne, of which is to resemble no other, simply itself.' Whether crafting the broad harmony of 'La Française' or the singular focus of 'Comtes de Champagne', Taittinger blends with purpose, mission and meaning.
The result is Champagne that speaks not only of place, but of philosophy - a quiet tension between craft and expression, tradition and reinvention. And at the centre of it all is blending: equal parts art, discipline, and the patience to listen.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
AB Science announces the successful completion of a 2.55 million euros private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENT Paris, August 4, 2025, 8am CET AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 2.55 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 2,276,787 new ordinary shares of the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 3.34% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 3.23% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on August 1st, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 24, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.12 (including share issue premium), representing a facial discount of 24.68% (i.e. EUR 0.3669) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. August 1st and July 31 and 30, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 17.87% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.71 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 2,276,787 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 3.89 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of August 1st, 2025, is equal to EUR 0.3877 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to August 11, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 704,695.95 (or EUR 727,463.82 in the event of exercise of all BSAs). It will be comprised of 63,706,916 ordinary shares (or of 65,983,703 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. To the Company's knowledge, immediately prior to completion of the Private Placement and after completion of the Private Placement, the breakdown of the Company's share capital is as follows: Shareholders Before the capital increase After the capital increase (before exercising the warrants) After the capital increase and exercise of the warrant Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) A. Moussy 7 345 396 10,77% 17,57% 7 345 396 10,42% 17,12% 7 345 396 10,10% 16,69% AMY SAS (3) 12 273 000 18,00% 14,20% 12 273 000 17,42% 13,84% 12 273 000 16,87% 13,49% Subtotal concert A. Moussy 19 618 396 28,77% 31,77% 19 618 396 27,84% 30,96% 19 618 396 26,97% 30,18% Other investors members of the concert 2 625 327 3,85% 5,97% 2 625 327 3,73% 5,82% 2 625 327 3,61% 5,67% Actions in the pact 1 123 902 1,65% 4,24% 1 123 902 1,59% 4,13% 1 123 902 1,54% 4,02% Actions outside the pact 1 501 425 2,20% 1,74% 1 501 425 2,13% 1,69% 1 501 425 2,06% 1,65% Total concert 22 243 723 32,62% 37,74% 22 243 723 31,56% 36,78% 22 243 723 30,58% 35,86% Other investors above 5% 6 888 610 10,10% 9,33% 6 888 610 9,78% 9,09% 6 888 610 9,47% 8,86% Other investors 39 060 475 57,28% 52,93% 41 337 262 58,66% 54,14% 43 614 049 59,95% 55,28% Total 68 192 808 100,00% 100,00% 70 469 595 100,00% 100,00% 72 746 382 100,00% 100,00% (1) All classes of shares are affected. The number of ordinary shares amounts to 61,430,129 before the Private Placement, 63,706,916 after the Private Placement (but before exercise of the BSAs), and 65,983,703 after the Private Placement and exercise of the BSAs.(2) The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).(3) AMY SAS is a company controlled by A. Moussy. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.97% on a non-diluted basis and 0.77% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on August 7, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 24, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. August 1st, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). August 4, 2025 Publication of this press of the Information Document. August 7, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. August 7, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. August 11, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - August 2025 Press Release US VFSign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Elis: Disclosure of trading in own shares occured from July 28 to August 1, 2025
Disclosure of trading in own shares occurred from July 28 to August 1, 2025 Saint-Cloud, August 4, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from July 28 to August 1, 2025 under the buyback program authorized by the 24th resolution of the General Shareholders' Meeting of May 22, 2025 and announced on March 6, 2025: Aggregated presentation: Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code) ELIS SA 969500UX71LCE8MAY492 07/28/2025 FR0012435121 20,000 25.0413 XPAR ELIS SA 969500UX71LCE8MAY492 07/29/2025 FR0012435121 24,000 25.0691 XPAR ELIS SA 969500UX71LCE8MAY492 07/30/2025 FR0012435121 32,000 24.8650 XPAR ELIS SA 969500UX71LCE8MAY492 07/30/2025 FR0012435121 9,000 24.7547 DXE ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 32,310 24.0257 XPAR ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 25,520 24.0674 DXE ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 6,000 23.8797 TQE ELIS SA 969500UX71LCE8MAY492 07/31/2025 FR0012435121 4,500 23.9301 AQE ELIS SA 969500UX71LCE8MAY492 08/01/2025 FR0012435121 22,627 24.3029 XPAR ELIS SA 969500UX71LCE8MAY492 08/01/2025 FR0012435121 5,711 24.1992 DXE Total 181,668 24.4979 The purpose of the own shares purchase operations is (i) to cover maturing performance share plans and to allocate free shares to employees as part of the contribution to the Elis for All 2025 international employee shareholding plan, and (ii) to be cancelled in accordance with the 26th resolution of the Combined General Meeting of May 22, 2025. Contacts Nicolas BuronDirector of Investor Relations, Financing & TreasuryPhone: + 33 (0)1 75 49 98 30 - Charline LefaucheuxInvestor Relations Phone: + 33 (0)1 75 49 98 15 - Attachment Elis - Disclosure of trading in own shares occured from July 28 to August 1, 2025
Yahoo
2 hours ago
- Yahoo
Atos recognized as Supplier Engagement Leader by CDP for the 5th time
Press Release Atos recognized as Supplier Engagement Leader by CDP for the 5th time Paris, France – July 30, 2025 – Atos has been recognized for the fifth time by the Carbon Disclosure Project (CDP) by being included in the prestigious Supplier Engagement Rating Leaderboard for its leadership in corporate supply chain engagement on climate change and environmental issues. Only the top companies which disclosed information for the full CDP Climate questionnaire secured a place on the CDP Supplier Engagement Leaderboard. Atos tackles its Scope 3 emissions, which represent the largest share (95.5%) of its GHG1 footprint, by working closely with its suppliers to assess and improve their sustainability performance. In 2024, 75%2 of Atos Group spend was made towards suppliers who had undergone a sustainability assessment. Atos suppliers can demonstrate their commitment to fight climate change by signing a dedicated contract clause with Atos whereby they are required to measure and report their emissions and commit to science-based climate targets. Atos also provides guidance and support to suppliers with lower sustainability maturity to help them initiate or improve their decarbonization journey. Marie de Scorbiac, Head of Investor Relations and CSR, Atos Group, said : 'Atos' inclusion on the 2024 CDP Supplier Engagement Leaderboard is a reward for its long-standing commitment to sustainable procurement and its rigorous, transparent reporting practices for customers, investors, and regulators. This recognition acknowledges the importance of our approach to engaging our suppliers and stakeholders.' Atos aims to continue engaging more suppliers on sustainability issues across its value chain and support them in their decarbonization journey to meet its GHG emission reduction targets and contribute to the fight against climate change. *** About Atos Group Atos Group is a global leader in digital transformation with c. 72,000 employees and annual revenue of c. € 10 billion, operating in 68 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos is a SE (Societas Europaea) and listed on Euronext Paris. The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space. Press contact Isabelle Grangé | | +33 (0) 6 64 56 74 88 1 GHG - GreenHouse Gas2 Atos 2024 Universal Registration Document Attachment PR-Atos recognized as Supplier Engagement Leader by CDP for the 5th time